Core Viewpoint - The article discusses the rising threat of Chikungunya virus, particularly in Guangdong, China, and highlights the approval of two vaccines, VIMKUNYA and Ixchiq, which are effective in preventing the disease for individuals aged 12 and above [1][4][6]. Group 1: Disease Overview - Chikungunya is a mosquito-borne viral disease characterized by acute symptoms such as fever, rash, fatigue, and severe joint pain, with a low mortality rate but high incidence [4]. - Approximately 50% of Chikungunya patients experience debilitating long-term symptoms, which may worsen with age [4]. - The disease primarily spreads in tropical and subtropical regions, with local transmission in China being rare [3]. Group 2: Current Situation - In Guangdong, the number of confirmed Chikungunya cases has exceeded 3,000, with occasional imported cases reported in Beijing [4]. - The World Health Organization has warned that around 5.5 million people across 119 countries and regions are at risk of Chikungunya [4]. Group 3: Vaccine Approvals - VIMKUNYA, developed by Bavarian Nordic, is the first Chikungunya vaccine approved by the FDA for individuals aged 12 and older [6][8]. - Ixchiq, developed by Valneva, is another vaccine aimed at protecting individuals aged 12 to 64 from Chikungunya virus infection [10][12]. Group 4: Vaccine Efficacy and Safety - VIMKUNYA demonstrated a 97.8% neutralizing antibody response within 21 days post-vaccination in clinical trials involving over 3,500 participants [8]. - Common side effects of VIMKUNYA include injection site pain, fatigue, headache, and muscle pain [9]. - Ixchiq may cause side effects such as leukopenia, neutropenia, lymphopenia, headache, fatigue, and elevated liver enzymes, particularly in individuals over 65 or those with immune deficiencies [14].